ACU vs SKYA vs RVP Stock Comparison

Acme United, SkyAI and Retractable Technologies Prices as of Nov 5, 2026 Peers: Industry group
1 more company in this comparison (UEEC) Create a free account to keep reading and compare up to 10 companies.
ACU Acme United Corp
$69.02 +9.4% 1M +81.4% 1Y
Market cap
$264.61M
P/E
26.9x
Revenue (TTM)
$211.60M
Div. yield
0.93%
Medical Supplies Healthcare
8 wins
SKYA SkyAI, Inc.
$2.92 +55.3% 1M -30.6% 1Y
Market cap
$210.51M
P/E
–
Revenue (TTM)
$174.18K
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

10 decided of 12

Acme United leads on 8 of the 12 questions below (Acme United 8, SkyAI 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionACUSKYARVPLeader
Larger companyMarket capitalisation $264.61M $210.51M $17.06M ACU
Cheaper on earningsLower P/E, profitable companies only 26.9x -0.5x -4.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.2x 0.0x — SKYA
Faster revenue growthRevenue growth, trailing twelve months +9.0% +108.0% -11.2% SKYA
More profitableNet margin, trailing twelve months 4.6% -228,220.7% -10.6% ACU
Better return on capitalReturn on invested capital 7.3% — -31.4% ACU
Less leveragedLower net debt / EBITDA 1.1x — 2.6x ACU
Higher dividend yieldTrailing dividend yield 0.93% — — –
Better 1-year returnPrice return, last 12 months +81.4% -30.6% -33.5% ACU
Better 5-year returnAnnualised price return, 5 years +14.0%/yr — -42.5%/yr ACU
Less volatileAnnualised volatility, 1 year 30.9% 104.7% 39.9% ACU
Higher overall scoreMean of the five percentile scores vs peers 71/100 27/100 53/100 ACU

Percentile Scorecard

ACUSKYARVP

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisACUSKYARVP
Valuation 95 #13 of 229 4 #221 of 229 73 #63 of 229
Growth 57 #96 of 221 4 #213 of 221 35 #145 of 221
Profitability 81 #41 of 210 1 #209 of 210 37 #132 of 210
Financial Health 57 #104 of 240 95 #13 of 240 66 #82 of 240
Shareholder Returns 65 #52 of 147 33 #99 of 147 –
Overall 71 27 53
  • ACU ranked among 247 companies in Medical Devices and Diagnostics
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics
  • RVP ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodACUSKYARVPSPY
1 month +9.4%+55.3%-16.2% -5.9%
3 months +23.2%+149.6%-14.9% -4.6%
6 months +65.0%+56.1%-19.1% +0.2%
Year to date +71.2%+43.8%-26.2% +7.5%
1 year +81.4%-30.6%-33.5% +8.2%
3 years +107.6%-99.9%-47.2% +68.3%
3 years, per year +27.6%-90.0%-19.2% +19.0%
5 years +92.8%—-93.7% +56.5%
5 years, per year +14.0%—-42.5% +9.4%
10 years +222.5%—-77.6% +251.5%
10 years, per year +12.4%—-13.9% +13.4%

Risk

MeasureACUSKYARVPSPY
Volatility, 1Y 30.9%104.7%39.9% 13.6%
Downside volatility, 1Y 24.8%104.1%44.3% 14.2%
Beta vs S&P 500, 1Y 0.282.150.11 1.00
Return / volatility, 1Y 2.64-0.29-0.84 0.60
Max drawdown, 5Y -41.7%-100.0%-94.0% -25.4%
From 52-week high -2.7%-30.6%-33.5% -5.9%
52-week high $70.92$4.21$0.86 $779.14
52-week low $35.50$0.95$0.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleACUSKYARVP
P/E now vs peer median 26.9xmedian 26.9x -0.5xmedian 26.9x -4.7xmedian 26.9x
P/S now vs peer median 1.3xmedian 2.9x 1,209xmedian 2.9x 0.5xmedian 2.9x
EV/EBITDA now vs peer median 11.8xmedian 17.5x -0.5xmedian 17.5x 1.5xmedian 17.5x
P/FCF now vs peer median 17.1xmedian 26.4x -1.0xmedian 26.4x -3.3xmedian 26.4x
P/B now vs peer median 2.2xmedian 2.3x 1.3xmedian 2.3x 0.2xmedian 2.3x
PEG now vs peer median 0.90median 0.88 0.01median 0.88 0.22median 0.88

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsACUSKYARVP
Revenue $211.60M $174.18K $33.90M
Gross profit $84.82M $324.68K -$491.51K
Operating income $14.48M -$374.36M -$22.68M
Net income $9.82M -$397.51M -$3.37M
Free cash flow $15.48M -$201.93M -$5.11M
R&D – $475.55K $682.03K
EPS (diluted) $2.37 $-5.51 $-0.12
Cash & equivalents $5.04M $12.07M $2.64M
Total debt $32.33M – $715.92K
Shares (diluted) 4.14M 72.09M 29.94M
Enterprise value $246.63M $165.22M -$129.34M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricACUSKYARVP
P/E 26.9x -0.5x -4.7x
P/FCF 17.1x -1.0x -3.3x
P/Operating cash flow 10.1x -14.6x -3.4x
P/S 1.3x 1,209x 0.5x
P/B 2.2x 1.3x 0.2x
P/Tangible book 3.0x 16.2x 0.2x
EV/EBITDA 11.8x -0.5x 1.5x
EV/EBIT 20.2x -0.5x 1.0x
EV/Revenue 1.4x 1,139x -0.7x
EV/FCF 18.9x -1.0x 4.3x
EV/Operating cash flow 11.2x -13.8x 4.5x
PEG (3Y EPS CAGR) 0.90 0.01 0.22

Growth

14 metrics
MetricACUSKYARVP
Revenue growth (1Y) 9.0% 108.0% -11.2%
Revenue CAGR (3Y) 3.1% 19.4% -14.7%
Gross profit growth (1Y) 11.0% – 81.2%
Gross profit CAGR (3Y) 8.5% – -26.8%
Operating income growth (1Y) 3.3% -8,055% -2.3%
Operating income CAGR (3Y) 20.1% -240.7% -11.7%
Net income growth (1Y) -5.1% -54,854% 61.4%
Net income CAGR (3Y) 36.0% -268.2% -23.9%
EPS growth (1Y) -5.9% -658.6% 59.8%
EPS CAGR (3Y) 29.7% -100.6% -21.9%
Operating cash flow growth (1Y) 43.2% -356.8% 58.8%
Operating cash flow CAGR (3Y) 12.0% -24.4% -16.8%
Free cash flow growth (1Y) 26.7% -6,031% 62.3%
Free cash flow CAGR (3Y) 1.5% -196.9% 20.0%

Profitability

14 metrics
MetricACUSKYARVP
Gross margin 40.1% 186.4% -1.4%
EBITDA margin 11.7% -214,892% -43.9%
Operating margin 6.8% -214,931% -66.9%
Pretax margin 5.9% -221,236% -9.9%
Net margin 4.6% -228,221% -10.6%
FCF margin 7.3% -115,934% -15.1%
Operating cash flow margin 12.3% -8,259% -14.6%
Return on equity 8.2% -280.7% -4.7%
Return on assets 5.0% -276.3% -2.4%
Return on invested capital 7.3% – -31.4%
Return on capital employed 8.9% -223.1% -18.0%
Asset turnover 1.1x 0.0x 0.2x
Cash conversion (OCF / net income) 2.7x 0.0x 1.5x
Stock comp / revenue 0.9% 52,451% –

Financial Health

11 metrics
MetricACUSKYARVP
Debt / assets 16.1% – 0.5%
Debt / equity 0.3x – 0.0x
Net debt / EBITDA 1.1x – 2.6x
Debt / FCF 2.1x – -0.1x
Liabilities / assets 39.5% 1.9% 48.6%
Equity / assets 60.5% 98.1% 51.4%
Interest coverage – – -278.8x
Current ratio 3.2x 5.3x 4.9x
Quick ratio 1.3x 4.4x 3.7x
Cash ratio 0.1x 4.2x 3.0x
Altman Z-score 4.50 29.80 0.43

Shareholder Returns

7 metrics
MetricACUSKYARVP
Dividend yield 0.9% – –
Net buyback yield -0.2% -0.6% –
Shareholder yield 0.7% -0.6% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusACUSKYARVP
Forward P/E 25.2xFY2026 0.0xFY2026 –
EPS, next fiscal year $2.74FY2026 $2,362.06FY2026 –
EPS growth, next FY +10.0%FY2026 – –
EPS growth, the year after +20.4% – –
Revenue, next fiscal year $217.94MFY2026 $70.01MFY2026 –
Revenue growth, next FY +10.9%FY2026 +34,200.1%FY2026 –
Revenue growth, the year after +0.4% +17.5% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersACUSKYARVP
Held by institutions 73.5% – 8.8%
Institutions holding 84 – 32
Change in shares held, QoQ +1.3% – +5.9%
Institutions buying 47 – 10
Institutions selling 21 – 4
Buyers to sellers 2.24 – 2.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ACUSKYARVP
ACU 1.00 -0.02 0.06
SKYA -0.02 1.00 0.03
RVP 0.06 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ACU, SKYA and RVP?

Acme United (ACU) is the largest by market capitalisation: Acme United (ACU) $264.61M, SkyAI (SKYA) $210.51M, Retractable Technologies (RVP) $17.06M.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Acme United (ACU) +9.0%, SkyAI (SKYA) +108.0%, Retractable Technologies (RVP) -11.2%.

Which company is more profitable?

Acme United (ACU) has the highest net margin (Acme United (ACU) 4.6%, SkyAI (SKYA) -228,220.7%, Retractable Technologies (RVP) -10.6%). On return on invested capital, Acme United (ACU) leads (Acme United (ACU) 7.3%, Retractable Technologies (RVP) -31.4%).

Which stock has performed better?

Over the past year Acme United (ACU) returned the most: Acme United (ACU) +81.4%, SkyAI (SKYA) -30.6%, Retractable Technologies (RVP) -33.5%. Over five years, Acme United (ACU) compounded fastest (Acme United (ACU) +14.0%/yr, Retractable Technologies (RVP) -42.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Acme United (ACU) 0.93%. SkyAI (SKYA) and Retractable Technologies (RVP) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Acme United (ACU) has been the steadiest (Acme United (ACU) 30.9%, SkyAI (SKYA) 104.7%, Retractable Technologies (RVP) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ACU, SKYA and RVP?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Acme United (ACU) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.